June 28, 2024 Update: Claims Review are in progress and you will be notified by the Claims Administrator in writing if more information is required.
The Settlement Agreement was approved Canada-wide on November 8, 2022, and the approval became final on February 6, 2023. You and your family members may be entitled to compensation if you were prescribed in Canada, ingested, and subsequently developed an addiction to OxyContin® and/or OxyNEO® tablets at any time between January 1, 1996 and February 28, 2017.
The Class Members are defined as:
All persons in Canada, including their estates, who at any time between January 1, 1996 and February 28, 2017 were prescribed in Canada and ingested OxyContin® tablets and/or OxyNEO® tablets, manufactured, marketed and/or sold or otherwise placed into the stream of commerce in Canada by one or more of the Defendants (the “Class” or “Class Members”); and
All persons in Canada who by virtue of a personal relationship to a Class Member have a Family Law Act, R.S.O. 1990, c.F.3 (or equivalent legislation in other provinces or territories) derivative claim (the “Family Class” or “Family Class Members”).
The Canada-wide Settlement provides for the payment of $20,000,000 (Canadian dollars) which will be used to pay Class Member compensation, the administration of the Settlement, health care expenses incurred by the Provincial Health Insurers, and Class Counsel’s legal fees, disbursements, and applicable taxes. The amount that will be paid to eligible Class Members will be unknown until after the end of the Claims Period, and after all administration has been completed.
For more information about how compensation is determined, you should review the Settlement Agreement, the proof requirements in FAQ 9 or contact the Claims Administrator (see Contact Us tab) or Class Counsel (see FAQ 18).
Check out the Frequently Asked Questions section for more details on the Settlement.
PLEASE DO NOT CONTACT PURDUE OR THE COURTS FOR INFORMATION.